The stem cell therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber-based ex vivo stem cell expansion technology and proangiogenic growth factors overexpression of human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The progenitor cells were expanded ϳ225-fold on nanofiber-based serum-free ex vivo expansion culture technique without inducing differentiation. The expanded cells express high levels of stem cell homing receptor, CXCR4, and adhesion molecule, LFA-1. The nanofiber-expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. These expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and this effect was further augmented by VEGF 164 and PDGF-BB, growth factor overexpression. The data indicate that nanofiber-based ex vivo expansion technology can provide an essential number of therapeutic stem cells. Additionally, proangiogenic growth factors overexpression in progenitor cells can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.
INTRODUCTION
derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The self-renewal, proliferation, and differentiation of The limited availability and the compromised quality of endothelial progenitor cells (EPC) in bone marrow hematopoietic stem/progenitor cells (HSPCs) is tightly regulated in vivo by an array of signals emanating from and peripheral circulation (10) and adults in disease states (7) limit its therapeutic use for successful cell-their microenvironment, termed the hematopoietic stem cell (HSC) niche (26) . Ex vivo expansion of human stem based therapy for a variety of ischemic diseases. To overcome this obstacle, an ex vivo repair of a patient's cells has been carried out either by a biological or biomaterials approach (27) . In a biological approach, less stem cells through growth factor-enriched culture and/or genetic modification prior to autologous or allogeneic defined stromal layers were used for expansion, which may also produce negative regulators of hematopoiesis transplantation has been attempted with limited success (23). Here we report a nanofiber-based ex vivo stem cell (27) . A stromal-free suspension culture has been rapidly expansion technology and proangiogenic growth factor transfection of the human umbilical cord blood (UCB)-adopted as an alternative to stromal layer culture for HSC expansion due to their chemically defined nature. Limited (14) . Electrospinning, PAAc grafting, and amination of PES nanofibers were carried out according to This method involves the use of various combinations of growth factors and cytokines to substitute for the reg-the procedure described elsewhere in detail (4) . ulatory signals provided by stromal cells (11, 29) . In our Ex Vivo CD133 + Hematopoietic Cell earlier studies using stromal-free culture, we have Expansion Cultures shown that the human umbilical cord blood (UCB)derived CD34 + cells can be expanded on aminated na-Purified recombinant human stem cell factor (SCF), Flt-3 ligand (Flt3), TPO, and IL-3 were purchased from nofibers for 10 days using serum-free medium (4) . However, their functionality and effectiveness have yet to be Peprotech Inc. (Rocky Hill, NJ, USA). The StemSpan SFEM medium was purchased from StemCell Technolo-clearly defined.
Recent study with plasmid vectors of VEGF-A 164 or gies (Vancouver, BC, Canada). Nanofiber meshes were securely glued to the bottoms of wells of a 24-well PDGF-BB, or a combination of the two (12) , indicated that VEGF-A 164 increased capillary density more than tissue culture plate. Eight hundred CD133 + cells were seeded onto each scaffold in 0.6 ml StemSpan TM serum-PDGF-BB, and PDGF-BB preferentially stimulated arteriolar growth. The above combination increased both free expansion medium, which consists of 1% BSA, 0.01 mg/ml recombinant human insulin, 0.2 mg/ml hu-capillaries and arterioles. Furthermore, combined stimulation with VEGF-A, fibroblast growth factor 2 (FGF-man transferrin, 0.1 mM 2-mercaptoethanol, and 2 mM L-glutamine in Iscove's MDM, supplemented with 0.04 2), or PDGF-BB has emerged as a potent strategy for therapeutic angiogenesis (15) . mg/ml low-density lipoprotein (Athens Research and Technology Inc., USA), 100 ng/ml SCF, 100 ng/ml Flt3, In the present study, with the aim of increasing neovascularization as a treatment strategy for myocardial 50 ng/ml TPO, and 20 ng/ml IL-3. Cells were cultured at 37°C in an atmosphere containing 5% CO 2 for 10 ischemia and peripheral vascular disease, we examined the feasibility of expanding UCB-derived CD133 + pro-days without medium change. Cells were harvested after 10 days of expansion. All substrates were washed once genitor cell population using nanofiber scaffold-based ex vivo expansion culture technique. We also utilized a with non-trypsin cell dissociation solution and twice with 2% FBS Hanks' buffer at 5-10 min intervals be-bicistronic vector, in which both VEGF-A 164 and PDGF-BB genes with internal ribosomal entry site (IRES) un-tween each wash. The cell suspensions collected were then concentrated through centrifugation at 500 × g for der CMV promoter (coupled VIP) are overexpressed in ex vivo-expanded UCB-derived progenitor stem cells.
10 min. Aliquots of the concentrated cells were then used for cell counting by a hemocytometer, flow cytom-MATERIALS AND METHODS etry analysis, as well as for further studies. CD133 + Cell Isolation Flow Cytometry Fresh human cord blood was obtained from Univer-For flow cytometric analysis cell surface markers sity Hospitals Case Medical Center after IRB approval were blocked with FCR Blocking Reagent (1:5; Miltenyi and written consent from donors. Cord blood was pro-Biotec Inc.) and incubated for 20 min at 4°C with the cessed following the similar protocol published earlier following antibodies: anti-CD34-PE, and anti-CD133/2 (5). The heparinized cord blood was diluted with PBS FITC (all from Miltenyi Biotec Inc). Isotype controls and carefully layered over 10 ml of Ficoll. After 30-min were purchased from BD Pharmingen. After incubation centrifugation in a swinging bucket rotor at 14000 rpm, cells were washed with MACS sorting buffer and anathe upper layer was aspirated and the mononuclear cell lyzed using a FACS Calibur flow cytometer (Becton layer was collected. Following labeling with magnetic Dickinson, Heidelberg, Germany). Dead cells were exbead conjugated anti-CD133 (CD133) monoclonal anticluded via propidium iodide staining. Data analysis was body (Miltenyi Biotec Inc, Bergisch Gladbach, Gerperformed with BD Cell Quest software. The Milanmany), two cell separation cycles (with different col-Mulhouse gating method was used for cell enumeration, umns) were performed using the AutoMACS cell sorter where a double gating (CD133 and CD34 + ) strategy was (Miltenyi Biotec) according to the manufacturer's protoused to identify the primitive hematopoietic progenitor col and reagents. After separation, purity of the cell cell population in the ex vivo expansion cultures. product was determined by flow cytometry.
Fluorescently labeled antibodies for other cell surface Electrospinning, Surface Grafting, and Amination markers (CXCR4, von Willebrand Factor, CD31, CD14, of PES Nanofiber Mesh MHC class I, MHC class II, CD69, CD3, Mac-I, LFA-1, and CD86) were purchased from BD Biosciences All chemicals were purchased from Sigma-Aldrich (USA) unless otherwise stated. PES granules (MW (USA). The cell samples were incubated at 4°C for >30 min in 2% FBS Hanks' buffer in the presence of various 55,000) were purchased from Goodfellow Cambridge antibody combinations. After antibody staining, cells chambers were stained with Giemsa and counted under microscope. were washed twice using Hanks' buffer and fixed in 1% paraformaldehyde. Cells were analyzed by two-color flow cytometry on a FACS Calibur analyzer (BD Bio-Nanofiber-Expanded Progenitor Cell-Induced Neovascularization in a NOD/SCID Mice Hind sciences). Relevant isotype controls were also included to confirm specificity and for compensation setting. At
Limb Vascular Injury Model least 20,000 events were acquired.
All animal experiments were performed in accordance with the guidelines published in the Guide for the
Genetic Manipulation of Stem Cells
Care and Use of Laboratory Animals (NRC publication), Freshly isolated human CD133 + MACS sorted cells and under the protocols approved by the Institutional or nanofiber-expanded cells were transfected with either Animal Care and Use Committee at Case Western Re-GFP containing vector (pmaxGFP) or VIP vectors serve University. Female NOD/SCID mice (7 weeks (VEGF IRES and PDGF in pAMFG vector, generous old) were purchased from Jackson laboratory (Bar Hargift from Dr. Blau, Stanford University, CA) using a bor, ME). Mice were anesthetized with an IP injection human CD34 cell Nucleofector kit (Amaxa Inc.) followof a cocktail of ketamine, xylazine, and acepromazine, ing the manufacturer's protocol. In brief, 1-3 × 10 6 cells the proximal right femoral artery was ligated at two were transfected with 2-4 µg of plasmid DNA in 100 points 3 mm apart, and the artery between the ligatures µl of CD34 cell Nucleofector solution and using Amaxa was transected. Studies were performed with four Electroporator programs: U-008 or U-001 (Amaxa Inc.). groups of mice. Each group (6-9 mice) was injected After transfection cells were cultured with DMEM comwith either media alone, freshly isolated CD133 + cells plete media or as stated for further studies.
(5 × 10 5 cells/mouse), 10-day nanofiber-expanded cells, or VIP transfected nanofiber-expanded cells via intra-Enzyme-Linked Immunosorbent Assay (ELISA) ventricular delivery in 300 µl volume. At baseline, post-One million nanofiber-expanded cells transfected ligation, and days 7, 14, 21, and 28, mice were assessed with coupled VIP vector or empty vector were cultured for functional recovery and blood flow. At day 28, the on a 24-well plate and cell culture supernatant was colmice were sacrificed and both right and left gastrocnelected at 24 or 48 h time points for ELISA. The levels mius muscles were excised. Half of each sample was of PDGF in the cell culture supernatants were quantisnap frozen and the other half was formalin fixed for tated using Quantikine human PDGF-BB ELISA kit further investigation. from R&D Systems (Minneapolis, MN).
Laser Doppler Perfusion Imaging Dil-Ac-LDL Uptake Assay
Mice were anesthetized and blood flow in the hind Dil-Ac-LDL uptake was performed following stanlimbs, and functional recovery was measured with a ladard protocol. After expansion of CD133 + cells on naser Doppler perfusion image analyzer (Moor Instrunofiber mesh for 10 days, cells were plated in glass botments Co. Ltd., Devon, UK) at baseline, after ligation, tom chamber slides for another 7 days with RPMI-1640 and at days, 7, 14, 21, and 28 after stem cell transplantacomplete media. After 7 days, cells were washed with tion. PBS and a serum-free RPMI-1640 containing 10 µg/ml Dil-Ac-LDL was added to the culture and incubated for Capillary Staining and Counting 4 h at 37°C. Medium was aspirated and cells were washed twice with PBS to remove free Dil-Ac-LDL.
To determine the capillary density in the border zone of each hind limb ischemia, tissues were dissected and Cells were then fixed with 3% formalin in PBS for 10 min followed by washing with PBS. Slides were moun-snap frozen in liquid nitrogen. Cryosections of frozen tissues were stained using an alkaline phosphatase kit ted with Vectashield includes DAPI. Slides were visualized under fluorescence microscope and digital photo-[Sigma FAST TM BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium tablets], which were graphs were recorded.
used for the detection of alkaline phosphatase activity Transwell Migration Assay and stained as a substrate precipitant. For quantification of positively stained vessels (predominantly endothe-Thirty thousand freshly isolated CD133 + cells or nanofiber-expanded cells were plated on the transwell up-lium), four sections within the necrosis border zone of each animal were analyzed by an investigator who was per chamber and migratory capacity was assessed in the presence or absence of stromal-derived factor (SDF) in blinded with respect to the cell treatment. Capillaries were counted in 12 randomly chosen high-power fields lower chamber, after 4 h of incubation at 37°C with 5% CO 2 in a humid chamber. Migrated cells to the lower (HPFs) in four sections per tissue and five animals per Nunc Internatinal Inc.) changing media on every third day. All cultures were performed in quadruplicate, incubated at 37°C in 5% CO 2 and 95% humidity, and scored after 14 days of culture by light microscopy. Immunocytochemistry/immunofluorescence staining for rhodamin conjugated F-Phalloidin (Invitrogen), smooth muscle myosin heavy chain (SM-MHC), smooth muscle α-actin, CD31, ICAM-1, VCAM-1, or von Willebrand factor (vWF) was performed (monoclonal antibody followed by either FITC-conjugated secondary goat anti-mouse IgG, or secondary reagent with DAPI). After several washing steps, samples were viewed under a fluorescence microscope (Leica, Germany). Cultured human umbilical vein endothelial cells (HUVEC) and NIH3T3 cells served as positive and negative controls, respectively.
RESULTS

Isolation of Fresh Umbilical Cord Blood-Derived Progenitor Cells and Ex Vivo Expansion
In general, via regular processing of human umbilical cord blood samples (60-80 ml sample volume), we were to a total of 4.5 million cells (225-fold amplification) over 10 days of culture using 24-well nanofiber-coated plates. Even at day 5, a 20-25-fold overall expansion group. The results were expressed as capillaries per was observed ( Fig. 1B ). high-power field.
Statistical Analysis
Phenotypic Characteristics of the Expanded Progenitor Cells All values were presented as mean ± SEM. One-way ANOVA with Scheffe's post hoc test for unequal sam-
The phenotype analysis indicated nearly 24% of the ple sizes was used to compare numeric data between total cells retain their CD133 expression and 93% of the the four experimental groups. Datasets consisting of two cells retain their CD34 expression ( Fig. 2) . A remarkgroups only were compared by unpaired Student's t-test.
able increase in expression of two important promigra-A level of p < 0.05 was considered as significant differtory and proadhesive molecules (CXCR4 and LFA-1, reence.
spectively) was observed. Mild to moderate expression of other myeloid markers was observed, such as CD14, In Vitro Differentiation Assay, Immunocytochemistry, CD86, vWF, CD31, or Mac-1, indicating that these exand Fluorescence Microscopy panded cells retain their progenitor characteristics. To assess the angiogenesis-relevant differentiation potential of cord blood-derived CD133 + cells, which
In Vitro Characterization of the Expanded were expanded on nanofibers for 10 days, separate series Progenitor Cells of cell products (n = 4) were cultivated and induced to adopt an endothelial or smooth muscle phenotype. Ten-AcLDL Uptake Assays. AcLDL uptake property of progenitor cell characteristics was analyzed in these ex-day expanded cells were either cultured with EGM2 medium or SMGM-2 medium (Cambrex Inc./Lonza Inc., panded cells (9) . The data demonstrated in Figure  3A -C, CD133 + cells expanded for 10 days on nanofiber-NJ) for another 14 days on chamber slides (Labtek, coated plates and further cultured on a serum-containing evaluated for the respective experiments ( Fig. 4E ). Cells were also cultured with smooth muscle growth medium differentiation media can uptake AcLDL efficiently.
(SMGM-2, Cambrex Inc./Lonza Inc., NJ) for another 14 Transwell Migration Assays. The invasive potential days for differentiation towards the smooth muscle linof expanded CD133 + cells in the presence or absence of eage. Under these conditions, early smooth muscle difstromal-derived factor (SDF)-1 was examined. After 4 h ferentiated markers such as F-Phalloidin, smooth muscle of incubation followed by Giemsa staining, a statistimyosin heavy chain (SM-MHC), and smooth muscle αcally significant (p < 0.01) twofold increase in migration actin were expressed on the differentiated cells ( Fig.  activity was observed for nanofiber-expanded cells com-5A-I). Respective isotype controls were also included pared to freshly isolated cells in the presence or absence and evaluated in the studies (Fig. 5G, H) . of SDF-1 (Fig. 3D ).
Genetic Modification of Expanded Stem Cells In Vitro Differentiation of the Expanded Progenitor Cells
We transfected pmaxGFP vector to the nanofiberexpanded progenitor stem cells. GFP expression was We assessed the ability of nanofiber-expanded cells to differentiate to smooth muscle and endothelial lin-verified after 24-h posttransfection under a fluorescence microscope. We observed approximately 90% transfec-eages upon culturing in differentiation media for an additional 14 days on chamber slides. Expressions of endo-tion efficiency using this approach (Fig. 6A, B) . We subsequently cultured these transfected cells under en-thelial specific markers (CD31, vWF, ICAM-1, VCAM-1) were assessed after an additional 14-day incubation in dothelial differentiation conditions for an additional 14 days. Microscopic examination showed that these cells endothelial cell growth medium (EGM2) (Cambrex Inc./ Lonza Inc., NJ). These cells were positive for the early appeared elongated in shape and endothelial-like in appearance ( Fig. 6C, D) . endothelial markers (Fig. 4A-D) . Isotype controls were
Transfection of Expanded Progenitor Cells expressed progenitor stem cells have reparative capacity through angiogenesis in a hind limb vascular injury (li-With Coupled VEGF and PDGF
gated the femoral artery) model of immunodeficient We transfected nanofiber-expanded HSPCs, using the NOD/SCID mice. Four groups of animals were used transfection protocol described above, with a coupled (6-9 animals per group): 1) expanded untransfected, 2) bicistronic vector containing VEGF and PDGF (obexpanded transfected with coupled VEGF and PDGF tained from Dr. Blau, Stanford University, CA). Using vector, 3) freshly isolated UCB-CD133 + cells, or 4) meimmunohistochemical staining observed for PDGF, dia only (no cells). Each group of animals was treated more than 60% transfection efficiency was demonstrated with stem/progenitor cell therapy (5 × 10 5 cells/animal, (Fig. 6E, F) . To evaluate PDGF secretion by these exintraventricular delivery). panded and transfected HSPC, ELISA was performed On post-cell delivery days 7, 14, 21, and 28, Doppler from the culture supernatants after 24 and 48 h postimaging studies were performed to evaluate blood flow transfection. After 48 h of posttransfection, we observed in the hind limbs (both ligated and nonligated). Data approximately fourfold induction of PDGF secretion were analyzed using a ratio of flow between the ischecompared to control vector-transfected cells (Fig. 6G) .
mic limb and the contralateral normal limb. Results from These results demonstrate that the nanofiber-expanded this Doppler study indicated that blood flow was much HSPC can be successfully transfected with the coupled higher in mice treated with expanded cells compared to VIP containing plasmid vector.
those treated with media alone. Moreover, in mice treated with expanded cells transfected with coupled In Vivo Functional Evaluation of Coupled VIP, blood flow was further augmented (from 43% to VIP-Transfected Progenitor Cells in a 62% recovery at day 28) ( Fig. 7A, B) .
Capillary counts NOD/SCID Hind Limb Vascular Injury Model
were performed as an anatomical marker of induced angiogenesis. Neovascularization was much more promi-We next sought to evaluate whether these nanofiberexpanded and proangiogenic growth factors genes over-nent and significantly increased in the group that re- In vitro differentiation of expanded stem cells to endothelial lineage. The 10-day nanofiber-expanded cells were recultured for another 14 days on chamber slides in EGM2 media. Early endothelial markers, such as CD31, vWF, and ICAM-1 and VCAM-1 (A-D) were studied using immunofluorescence staining; isotype-matched IgG were also used for control staining (E).
ceived expanded cells compared to the media-alone chemic signals to facilitate local therapeutic benefit. We transfected a GFP-containing vector (as described in the group, and most prominent in the group that received genetically modified expanded cells, verified either by previous section) to the cells. After 16 h of transfection, GFP vector transfected cells (5 × 10 5 cells/mouse) were immunostaining or total capillary counts (media; fresh CD133; nanofiber expanded; genetically modified ex-injected into hind limb ischemic mice via intraventricular delivery. Thirty-six hours after cell delivery, mice panded cells: 62, 73, 118, 156 capillaries/hpf, respectively) (Fig. 7C) . Taken together these data demonstrated were sacrificed and organs were harvested. Immunohistochemical analysis was performed on fixed and paraf-that genetically modified CD133 + cells with proangiogenic growth factors were significantly more potent than fin-embedded tissue sections using an anti-GFP Ab (Fig.  8A-J) . Appropriate controls were also evaluated. We that of unmodified cells or freshly isolated cells.
detected GFP-positive stem cells in the ischemic tissue Immunohistochemical Detection of Injected area, indicating the homing of these stem cells in the Stem/Progenitor Cells in the Ischemic Region target area of interest. In addition, GFP-positive cells of Mouse Hind Limb Vascular Injury Model were also detected in the lung, spleen, and bone marrow. GFP-positive cells were not found in the kidney, liver, Next, we sought to verify that nanofiber-expanded stem cells could physically migrate and respond to is-or brain tissues (data not shown). Figure 5 . In vitro differentiation of expanded stem cells to smooth muscle cells. Expanded cells were cultured with SMGM complete media for another 14 days. Early smooth muscle differentiated marker such as F-Phalloidin, smooth muscle myosin heavy chain (SM-MHC), and smooth muscle α-actin staining were performed (A-I). Respective isotype controls were also evaluated for representative assays (Fig. 5G, H) .
In summary, we have demonstrated that nanofibers genetic modification of expanded HSPCs with proangiogenic growth factors, and their enhanced vasculogenic could serve as an effective substrate to promote the expansion of functional hematopoietic stem/progenitor potential is demonstrated. Recent studies have shown that HSPCs, including autologous BM-derived CD133 + cells that retain progenitor cell phenotype of their freshly derived counterparts. We have also demonstrated that the cells, injected either via intracoronary infusion (2) or via intramyocardial injection (28) augmented vasculogen-expanded cells maintain the potential to differentiate into endothelial or smooth muscle lineages and can migrate to esis in patients with coronary artery ischemia (6) . However, the limited availability of progenitor cell popula-distant ischemic zones to provide local beneficial effects. Nanofiber-expanded cells are more potent than freshly tion in bone marrow and peripheral circulation (32) and compromised potential of these cells in aged patients isolated CD133 + cells in mediating neovascularization in a mouse model of hind limb ischemia. Furthermore, ex-and adults in disease states (8,13) has created problems for studying the mechanism of successful cell-based panded cells genetically modified with proangiogenic growth factors showed dramatic improvement in blood therapy in these patients.
To overcome the limitations of low numbers and flow restoration and neovascularization. compromised functional BM-or cord blood-derived DISCUSSION HSPCs, we tested a functional nanofiber expansion method that was introduced recently (4). We have In the present study, the feasibility of ex vivo expansion of HSPCs on nanofiber-coated plates and further achieved 225-fold expansion of HSPCs in 10 days of culture in a defined serum-free medium. The expanded enriched CD133 + cells. Injection of proangionenic growth factor-transfected HSPCs further increased the cells retained their progenitor cell phenotype. Nevertheless, over the course of nanofiber expansion, there was regenerative capacity of peripheral ischemia. Histological analysis of the hind limb muscle samples 4 weeks a significant decrease in CD133 + expression, but CD34 + expression was maintained at 93%. Our data indicate after stem cell treatment revealed improved vascular regeneration. Even though all animal groups that received that nanofiber-expanded cord blood-derived HSPCs are functionally more efficient in restoring tissue blood flow cell injections showed increased vascualrization compared to the control group, nanofiber-expanded and pro-in the ischemic hind limb muscle compared with freshly angiogenic growth factor-transfected cells showed a much ment of bone marrow-derived cells and collaborate with VEGF in the development of several types of neovascu-higher rate of vascualrization compared to either freshly isolated CD133 + cells or controls. larization (19) . In this study, the substantial increase in neovascularization potential of nanofiber-expanded and The mechanisms for HSPC-mediated vasculogenesis remain to be fully elucidated. Recent studies have ques-proangiogenic growth factor-transfected cells suggests that the interaction between upregulated CXCR4 ex-tioned the capacity of HSPCs to transdifferentiate into matured cells of injured tissues (22) . Mechanisms other pressed by the expanded cells with VEGF is important. However, the mechanism involved in the upregulation than myogenesis have also been suggested, such as angioblast-mediated vasculogenesis (16) and antiapoptotic of the nanofiber-expanded progenitor population is not clear. Further definitive studies are necessary to delin-effects of the paracrine factors secreted by HSPCs (31) . Paracrine mechanisms have been reported to mediate the eate the above signaling mechanism. Leukocyte function associated antigen 1 (LFA-1) is therapeutic effects of HSPCs in skeletal muscle ischemia. In a mouse model of hind limb ischemia, mouse considered as a marker of late stage stem cell maturation when expressed on CD34 + bone marrow cells (20, 30) . bone marrow stromal cells were shown to enhance collateral flow recovery and remodeling, and to attenuate
We observed that nanofiber-expanded UCB-derived CD133 + cells express high levels of LFA-1. In addition, muscle atrophy (17) . The effect was explained by the release of cytokines, such as VEGF and fibroblast Torensma et al. also showed that CD34 + LFA-1 − cells expressed LFA-1 within 24 h in culture (30). These in growth factor (FGF), from the progenitor cells. A variety of recombinant angiogenic growth factors have in-vitro findings indicate that LFA-1 is upregulated by default due to the lack of negative regulating signals from duced angiogenesis and collateral artery growth leading to improved regional blood flow and tissue recovery (1). stromal cells. The biological significance of elevated levels of LFA-1 expression in nanofiber-expanded cells A combination of VEGF and FGF-2 has also been shown to promote both angiogenesis and lymphangio-is not clear at this point and warrants further detailed study. genesis in several animal models (14) . However, as a novel approach of combining angiogenic growth factors
In summary, we have shown that functional nanofibers can substantially expand cord blood-derived HSPCs and HSPC-based cell therapy, we have shown a significant enhanced neovascularization effect, and a better re-in serum-free culture. The expanded cells retain their progenitor cell phenotype and provide an opportunity for covery of blood flow in murine ischemic muscle than HSPC infusion alone. In addition to the proangiogenic genetic manipulation prior to HSPC infusion. We have provided evidence that nonviral delivery of proangio-effect of VEGF, this markedly improved neovascularization may be enhanced by the maturation effect of PDGF genic factors VEGF and PDGF markedly enhanced the angiogenesis effect of HSPCs compared to untransfected (3) . PDGF has at least two distinct functions in proangiogenic signaling. On one hand, PDGF increases survival cells. This study has demonstrated the feasibility of a combined HSPC-based cell therapy with a proangio-and proliferation of endothelial cells and, on the other, PDGF regulates vessel growth via pericyte recruitment genic gene therapy approach, and propose the therapeutic potential of the nanofiber-expanded HSPCs in treat-and association to newly formed vessels (18) .
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The chemokine stromal-derived factor (SDF)-1 and REFERENCES its unique receptor CXCR4 are essential for normal car- gested that SDF-1 and CXCR4 contribute to the involve-
